Leukemia Research
Volume 29, Issue 6 , Pages 679-683 , June 2005

Rituximab therapy of lymphoma is enhanced by orally administered (1→3),(1→4)-d-β-glucan

  • Shakeel Modak

      Affiliations

    • Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 6397623; fax: +1 212 7442245.
    • ,
  • Guenther Koehne

      Affiliations

    • Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    • ,
  • Andrew Vickers

      Affiliations

    • Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    • Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    • ,
  • Richard J. O’Reilly

      Affiliations

    • Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    • ,
  • Nai-Kong V. Cheung

      Affiliations

    • Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA

Received 20 August 2004 ,Accepted 27 October 2004.

References 

  1. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–7368
  2. Ross GD, Cain JA, Myones BL, et al. Specificity of membrane complement receptor type three (CR3) for β-glucans. Complement Inflamm. 1987;4:61–74
  3. Cheung N, Modak S. Oral (1-3),(1-4)-beta-glucan syngergizes with anti-ganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res. 2002;8:1217–1223
  4. Cheung NK, Modak S, Vickers A, Knuckles B. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother. 2002;51:557–564
  5. Koehne G, Gallardo HF, Sadelain M, O’Reilly RJ. Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood. 2000;96:109–117
  6. Wei BR, Ghetie MA, Vitetta ES. The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice. Clin Cancer Res. 2000;6:631–642
  7. Vardi Y, Ying Z, Zhang CH. Two-sample tests for growth curves under dependent right censoring. Biometrika. 2001;88:949–960
  8. Sier CF, Gelderman KA, Prins FA, Gorter A. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. Int J Cancer. 2004;109:900–908
  9. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res. 2003;9:5866–5873
  10. Hong F, Yan J, Baran JT, et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models.. J Immunol. 2004;173:797–806
  11. Kennedy AD, Solga MD, Schuman TA, et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood. 2003;101:1071–1079
  12. Adachi Y, Okazaki M, Ohno N, Yadomae T. Enhancement of cytokine production by macrophages stimulated with (1→3)-beta-d-glucan, grifolan (GRN), isolated from Grifola frondosa. Biol Pharm Bull. 1994;17:1554–1560

PII: S0145-2126(04)00380-7

doi: 10.1016/j.leukres.2004.10.008

Leukemia Research
Volume 29, Issue 6 , Pages 679-683 , June 2005

Article Tools

* Image Usage & Resolution